EMA Issues 2026/2027 Flu Vaccine Strain Recommendations with Trivalent Shift and Platform-Specific Differences

Vaccine manufacturers targeting EU batch release for autumn 2026 are now working against a 15 June 2026 submission deadline after EMA published its finalised strain recommendations for the 2026/2027 seasonal influenza season, with platform-specific strain divergences adding a layer of regulatory complexity absent from prior cycles.

The CHMP endorsed the recommendations at its March 2026 plenary meeting, with an amendment adopted on 5 May 2026 adding strains for egg-derived and live-attenuated platforms. The update, reflected in a revised Annex I covering reagents for vaccine standardisation, means manufacturers must confirm which version of the recommendation governs their submission before filing a variation to their marketing authorisation.

Platform differences are operationally significant this season. Egg-based and live-attenuated manufacturers are directed to include A/Darwin/1454/2025 (H3N2) and B/Tokyo/EIS13-175/2025 (B/Victoria lineage), while cell-based manufacturers use A/Darwin/1415/2025 (H3N2) and B/Pennsylvania/14/2025 (B/Victoria lineage) instead. The H1N1 component, A/Missouri/11/2025, is common across all platforms. QA and regulatory teams managing multi-platform portfolios will need to ensure strain identity is correctly mapped per manufacturing process in each variation dossier.

The move to trivalent formulations marks the most structurally significant change to EU flu vaccine composition in several years. B/Yamagata has not been detected in global surveillance since March 2020 and carries no WHO or EMA recommendation for 2026/2027. Marketing authorisation holders still holding quadrivalent authorisations in markets where the trivalent transition is incomplete may produce a quadrivalent inactivated vaccine using the legacy B/Phuket/3073/2013 (B/Yamagata lineage)-like strain, consistent with prior WHO guidance, though this pathway is explicitly framed as transitional.

For plant heads and supply-chain planners, the trivalent shift affects antigen slot allocation, fill-finish scheduling, and any existing reference standard inventories tied to the B/Yamagata component. Reagent updates in Annex I should be reviewed against in-house standardisation protocols before seed lot preparation begins.

Marketing authorisation holders for centrally authorised vaccines should treat the 15 June 2026 variation submission deadline as the governing checkpoint for production planning alignment across QA, regulatory affairs, and manufacturing operations.

Source: European Medicines Agency (EMA) via ema.europa.eu, 7 May 2026 (updated from original 2026 publication to include egg-derived and live-attenuated strain recommendations).